Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET).
盐湖城，2025年1月8日（全球Newswire）-- 万基遗传公司（纳斯达克：MYGN），基因测试和精准医疗的领导者，今天宣布其管理团队成员将在1月15日（星期三）下午3:45（太平洋时间）在旧金山举行的第43届摩根大通医疗保健会议上进行演讲。
The presentation will be available through a live webcast in the investor relations section of Myriad's website at investor.myriad.com. An archived edition of the presentation will be available later that day.
此次演讲将在万基遗传公司网站的投资者关系部分通过直播网络广播，演讲的录像将于当天稍晚可用。
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .
关于Myriad Genetics
万基遗传是一家领先的基因检测和精准医疗公司，致力于提升所有人的健康和幸福。万基开发并提供基因检测，帮助评估患病风险或疾病进展，并在医疗专业领域指导治疗决策，在这些领域，基因洞察可以显著改善患者护理并降低医疗成本。欲了解更多信息，访问。
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
投资者联系
马特·斯卡洛
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
媒体联系
格伦·法雷尔
(385) 318-3718
PR@myriad.com
